List of Excipients in Branded Drug NITROGLYCERIN IN DEXTROSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	NITROGLYCERIN IN DEXTROSE	nitroglycerin, dextrose	51662-1332	ALCOHOL
HF Acquisition Co LLC DBA HealthFirst	NITROGLYCERIN IN DEXTROSE	nitroglycerin, dextrose	51662-1332	CITRIC ACID MONOHYDRATE
HF Acquisition Co LLC DBA HealthFirst	NITROGLYCERIN IN DEXTROSE	nitroglycerin, dextrose	51662-1332	DEXTROSE MONOHYDRATE
HF Acquisition Co LLC DBA HealthFirst	NITROGLYCERIN IN DEXTROSE	nitroglycerin, dextrose	51662-1332	HYDROCHLORIC ACID

Nitroglycerin in Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

Nitroglycerin in dextrose is an established intravenous vasodilator product with limited conventional patent protection and a low active-ingredient exclusivity barrier. Commercial value depends on formulation control, container compatibility, ready-to-use presentation, supply reliability, and hospital purchasing economics. The central technical issue is nitroglycerin adsorption into administration sets and containers, not the pharmacology of dextrose.

What is nitroglycerin in dextrose used for?

Nitroglycerin injection in dextrose is used intravenously for acute control of hypertension, perioperative hypertension, congestive heart failure associated with acute myocardial infarction, angina that does not respond to sublingual therapy, and controlled hypotension during surgery.[1]

The product is administered by controlled infusion. It is not interchangeable with sublingual nitroglycerin tablets, transdermal patches, topical ointments, or oral extended-release products.

Dextrose commonly functions as the infusion vehicle. It does not provide the therapeutic vasodilator effect. The active ingredient is nitroglycerin, also called glyceryl trinitrate.

What excipients are used?

The formulation typically contains:

Component	Function
Nitroglycerin	Active vasodilator
Dextrose, usually 5%	Isotonic infusion vehicle and diluent
Water for injection	Solvent
pH adjustment, where applicable	Product stability and compatibility
Container and administration materials	Delivery system, with major impact on dose recovery

The exact composition depends on whether the product is supplied as a concentrate or as a premixed infusion. Some products use dextrose alone, while others use sodium chloride or a dextrose-sodium chloride vehicle. A manufacturer cannot assume that a formulation containing the same nominal nitroglycerin concentration is therapeutically equivalent without addressing delivery-system performance.

How does dextrose affect the nitroglycerin formulation?

Dextrose is a commercially familiar parenteral vehicle with broad hospital acceptance. Its primary benefits are low cost, established sterility and compendial infrastructure, and compatibility with routine intravenous infusion practice.

Its limitations are formulation-specific.

Chemical stability

Nitroglycerin is sensitive to environmental and packaging conditions. Product development must assess:

• Assay and degradation products over shelf life
• Exposure to light
• Temperature excursions
• Oxygen exposure and headspace
• Extractables and leachables
• Adsorption to container and tubing materials
• Sterility and particulate formation
• Compatibility with common infusion solutions

Dextrose itself is not a strong differentiator because 5% dextrose injection is widely available. The differentiating element is the combination of nitroglycerin concentration, container, closure, tubing compatibility, and validated storage conditions.

Osmolality and patient tolerance

A 5% dextrose vehicle is generally suitable for intravenous use when the product is infused through an appropriate line. Formulation changes that increase total osmolality can restrict administration sites or require central venous access. A manufacturer seeking a peripheral-infusion indication would need to support the claim with product-specific tolerability and administration data.

pH control

Nitroglycerin formulations generally do not rely on a complex buffer system. Excessive buffer capacity can introduce compatibility problems, alter degradation pathways, or increase the burden of parenteral safety testing. A low-excipient formulation is commercially attractive if it maintains stability without requiring specialized storage.

What container and tubing materials are critical?

Container closure and administration-set compatibility are the most important excipient-adjacent issues for nitroglycerin injection.

Nitroglycerin can be absorbed by polyvinyl chloride, or PVC, administration tubing. The FDA label states that adsorption can reduce the amount of nitroglycerin delivered to the patient and recommends use of non-absorptive tubing or appropriate dose adjustment when PVC tubing is used.[1]

Material strategy

A commercial product should evaluate:

Material or system	Commercial consideration
PVC tubing	Established and inexpensive, but can reduce delivered dose through adsorption
Polyolefin containers	Lower adsorption risk and suitable for premixed products
Low-sorbing tubing	Supports more predictable dose delivery
Glass bottles	Strong barrier properties but heavier, breakable, and less convenient
Multilayer films	Can improve handling and barrier performance, subject to extractables testing
Prefilled syringes	Useful for controlled settings, but require high-performance closure and dose-delivery validation

The product label must identify any required tubing or administration-set limitations. A formulation that is chemically stable in the bag but loses a substantial fraction of the dose in the line is not commercially robust.

Can a low-sorption container support patent protection?

Potentially, but the patent position would depend on claim drafting and technical evidence. A patent could target:

• A nitroglycerin-dextrose composition with defined concentration and impurity limits
• A container made from a specified polyolefin or multilayer material
• A low-adsorption administration system
• A method of reducing nitroglycerin loss during infusion
• A prefilled delivery device with validated dose recovery
• A packaging configuration that improves photostability or shelf life

Composition claims are likely to face prior-art pressure because nitroglycerin in dextrose is an old dosage form. Device, packaging, and measured-performance claims have a stronger chance of differentiation if they are tied to reproducible technical results.

What patents protect nitroglycerin in dextrose?

Nitroglycerin in dextrose is a mature generic injectable category. The active ingredient has been known for decades, and conventional dextrose vehicles are standard parenteral excipients. The principal commercial opportunity is therefore unlikely to depend on a broad, new-molecule patent.

Patent estate assessment

Patent category	Expected relevance
Nitroglycerin active-ingredient patents	Expired or commercially irrelevant
Conventional nitroglycerin injection composition patents	Likely expired or vulnerable to prior art
Dextrose vehicle patents	Generally unavailable for ordinary 5% dextrose use
Low-sorption container patents	Potentially relevant for differentiated products
Administration-set compatibility patents	Potentially relevant if claims are technically narrow
Premixed ready-to-use bag patents	Possible, but dependent on specific packaging and stability claims
Manufacturing-process patents	Possible for sterile fill, handling, or impurity control
Method-of-use patents	Limited value for established indications
Regulatory exclusivity	No expected new-molecule exclusivity

A current product-specific patent determination requires matching the exact manufacturer, dosage form, strength, and regulatory listing against the FDA Orange Book and relevant patent databases. The general category has no obvious basis for a new broad patent monopoly.[2]

What is the FDA regulatory status?

Nitroglycerin injection is an established prescription drug product regulated under the Federal Food, Drug, and Cosmetic Act. Generic versions generally proceed through an abbreviated new drug application, or ANDA, when the proposed product can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable generic requirements.[3]

A formulation with a materially different vehicle, container, delivery system, concentration, or administration profile may require a 505(b)(2) application rather than a conventional ANDA. The regulatory route depends on the degree of difference from the reference product and whether existing findings can be relied upon.

ANDA opportunity

An ANDA strategy is strongest where the proposed product matches the reference product in:

• Active ingredient
• Route of administration
• Dosage form
• Strength
• Inactive ingredients, subject to applicable FDA requirements
• Labeling, except for permitted differences
• Container closure and administration instructions

The commercial advantage is lower development cost and a faster path than a full new drug application. The disadvantage is limited freedom to claim differentiated dosing, novel delivery technology, or materially different clinical use.

505(b)(2) opportunity

A 505(b)(2) route may support:

• A novel premixed concentration
• A ready-to-use bag with a different container system
• A syringe or closed-system presentation
• A revised administration method
• A formulation with a different vehicle or stability profile
• A new product configuration designed to reduce adsorption

The 505(b)(2) pathway can create a more defensible product profile, but it carries greater clinical, CMC, and regulatory development requirements than a standard ANDA.

When does nitroglycerin in dextrose lose exclusivity?

Nitroglycerin in dextrose is already a mature product category. The relevant exclusivity question is not loss of market exclusivity for the molecule, but whether a specific manufacturer has a live patent, pediatric exclusivity period, or product-specific regulatory protection.

For conventional nitroglycerin injection:

• New-molecular-entity exclusivity is not relevant.
• Conventional active-ingredient patent protection is expected to be expired.
• Pediatric exclusivity is not expected to create a material barrier.
• Any remaining protection would most likely arise from product-specific formulation, packaging, device, or method claims.
• Generic entry is legally feasible where no unexpired, enforceable patent blocks approval or launch.

Orange Book listings must be reviewed by exact product and applicant because listing practices differ between reference products and approved generic products.[2]

What paragraph IV challenges and litigation affect the product?

The category has limited litigation value compared with high-revenue medicines. A paragraph IV challenge would be commercially relevant only if an approved reference product has an unexpired listed patent covering the specific nitroglycerin injection presentation.

Potential litigation issues include:

1. Whether a listed patent actually covers the proposed concentration or container.
2. Whether the patent claims the drug product, a method of use, or the delivery system.
3. Whether the proposed label creates inducement concerns.
4. Whether a low-sorption container is an essential element of the claimed invention.
5. Whether prior art discloses nitroglycerin in dextrose and the relevant packaging materials.

Because the core composition is old, a patent owner would likely rely on narrow formulation or delivery claims. Such claims may be enforceable if supported by unexpected stability or dose-recovery data, but they are more vulnerable to obviousness and anticipation challenges than claims directed to a new active pharmaceutical ingredient.

No specific active paragraph IV litigation or settlement should be assumed without a current product-level Orange Book and court-docket review.

What commercial opportunities exist?

The best opportunities are operational and formulation-driven rather than molecule-driven.

Ready-to-use premixed bags

A premixed bag can eliminate bedside dilution, reduce compounding errors, and improve pharmacy workflow. Key commercial variables are:

• Common hospital bag sizes
• Standard infusion concentrations
• Shelf life at room temperature
• Light protection
• Non-PVC availability
• Barcode and smart-pump integration
• Reduced preparation requirements

A ready-to-use product can compete on total cost of care even when its acquisition price exceeds that of a concentrate.

Low-sorption delivery systems

A validated low-sorption system can address the principal clinical limitation of conventional nitroglycerin infusion. Commercial claims must be supported by comparative dose-recovery studies using clinically relevant flow rates, tubing lengths, priming procedures, and contact times.

This opportunity is strongest in hospitals that have moved away from PVC tubing or require closed-system compatibility.

Concentrate and premix portfolio

A manufacturer could offer:

• Concentrated vial for hospital pharmacy dilution
• Premixed standard-strength bag
• Higher-strength bag for fluid-restricted patients
• Non-PVC presentation
• Small-volume syringe for procedural use

The portfolio should avoid unnecessary concentration proliferation. Each additional strength increases manufacturing complexity, medication-error risk, inventory burden, and labeling requirements.

Contract manufacturing and private-label supply

Nitroglycerin injection is suitable for hospital-contract and private-label strategies because buyers value continuity of supply. A manufacturer with sterile injectable capacity can pursue:

• Group purchasing organization contracts
• Hospital-system private labels
• Regional supply agreements
• Dual-source arrangements
• Emergency preparedness contracts

Supply reliability can be more valuable than marginal formulation novelty in a mature injectable market.

How strong is the patent estate?

The conventional patent estate is weak. A differentiated delivery platform can create a moderate, product-specific position if it demonstrates measurable performance advantages.

Asset	Patent strength	Commercial value
Nitroglycerin active ingredient	Low	Low
5% dextrose vehicle	Low	Low
Conventional vial presentation	Low	Moderate if supply is constrained
Premixed bag	Low to moderate	High operational value
Non-PVC container	Moderate if technically specific	Moderate to high
Low-sorption tubing system	Moderate	High in controlled infusion settings
Novel syringe or closed system	Moderate	Moderate to high
New indication	Low to moderate	Depends on clinical differentiation
Manufacturing impurity-control process	Moderate	Usually defensive rather than market-expanding

A defensible patent program should focus on a combination of composition, container, administration method, and measured dose recovery. Broad claims covering "nitroglycerin in dextrose" are unlikely to provide durable protection.

How does nitroglycerin in dextrose compare with competing products?

Product type	Main advantage	Main limitation
Nitroglycerin in dextrose	Familiar vehicle and broad hospital compatibility	Adsorption and preparation constraints
Nitroglycerin in saline	Useful where dextrose is undesirable	Similar tubing and delivery issues
Nitroglycerin concentrate	Lower shipping volume and flexible dilution	Requires pharmacy preparation
Premixed nitroglycerin bag	Reduces preparation steps	Higher packaging and logistics cost
Sublingual nitroglycerin	Rapid outpatient administration	Not suitable for titrated IV control
Transdermal nitroglycerin	Longer-duration delivery	Poor fit for rapid titration
IV sodium nitroprusside	Potent and rapidly titratable	Different safety, monitoring, and light-protection requirements

Nitroglycerin in dextrose competes primarily on infusion convenience, availability, and delivery reliability. It does not compete directly with every nitroglycerin dosage form because the clinical settings differ.

What generic entry risks exist?

Generic entry risk is high for conventional presentations because:

• The active ingredient is old.
• The clinical indications are established.
• Dextrose is a standard parenteral vehicle.
• Conventional formulation claims are likely to face extensive prior art.
• Hospitals can substitute among approved products when labeling and supply conditions permit.

Risk is lower for a differentiated product protected by a narrow patent covering a validated container or closed-system delivery platform. Even then, a competitor may design around the claim by changing the film, tubing material, concentration, or packaging configuration.

Key Takeaways

• Nitroglycerin in dextrose is a mature generic injectable category with limited broad patent protection.
• Dextrose is primarily a vehicle, not the source of commercial differentiation.
• Nitroglycerin adsorption to PVC tubing is the central formulation and delivery challenge.
• Low-sorption containers, non-PVC administration sets, ready-to-use bags, and prefilled devices offer the strongest commercial opportunities.
• Conventional products generally fit an ANDA strategy; materially differentiated presentations may require a 505(b)(2) application.
• New-molecule exclusivity is not relevant, and conventional nitroglycerin patent protection is expected to be expired.
• A meaningful patent program should focus on packaging, administration systems, stability, dose recovery, and manufacturing controls.
• Generic entry risk is high for ordinary nitroglycerin-in-dextrose products and lower for technically differentiated delivery systems.

FAQs

Can nitroglycerin in dextrose be administered through PVC tubing?

PVC tubing can adsorb nitroglycerin and reduce delivered dose. Product-specific labeling should identify compatible tubing and any required priming or dose-adjustment procedures.[1]

Is nitroglycerin in dextrose eligible for biosimilar competition?

No. Nitroglycerin is a small-molecule drug, so competition proceeds through generic drug pathways rather than the biosimilar framework.

Does a premixed nitroglycerin bag need a new patent?

No. A premixed bag can be approved without a new patent. Patent protection is optional and would depend on whether the packaging, formulation, or delivery system contains a patentable technical improvement.

Can a manufacturer claim a new use for nitroglycerin in dextrose?

A method-of-use claim may be possible only for a genuinely new, adequately supported use. Established hypertension, angina, heart-failure, and perioperative indications provide limited room for strong new-use protection.

What is the most defensible commercial differentiator?

The strongest practical differentiator is a ready-to-use, low-sorption, non-PVC delivery system with validated dose recovery, long shelf life, broad smart-pump compatibility, and reliable hospital supply.

References

1. U.S. Food and Drug Administration. (n.d.). Nitroglycerin injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA): Generics. Center for Drug Evaluation and Research. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/generic-drug-user-fee-amendments###